LCK抑制可逆转儿童T细胞急性淋巴细胞白血病的糖皮质激素耐药
研究通过反向蛋白阵列发现,泼尼松反应不良的儿童T细胞急性淋巴细胞白血病(T-ALL)患者中淋巴细胞特异性蛋白酪氨酸激酶(LCK)异常激活。LCK抑制剂(如达沙替尼)可诱导糖皮质激素耐药T-ALL细胞死亡,与地塞米松联用能逆转耐药,并在患者来源异种移植模型中验证。LCK过度激活通过钙调磷酸酶/活化T细胞核因子信号上调白介素-4(IL-4),抑制IL-4信号可增加耐药细胞的糖皮质激素诱导凋亡。
要点
- LCK在泼尼松反应不良的儿童T-ALL患者中异常激活。
- 达沙替尼等LCK抑制剂与地塞米松联用可逆转糖皮质激素耐药。
- LCK过度激活通过钙调磷酸酶/NFAT信号上调IL-4,抑制IL-4信号可增敏。
核心结论
- 研究结果提示一种可快速实施的辅助常规治疗并克服儿童T-ALL糖皮质激素耐药的方法。
研究设计与样本
- 研究采用反向蛋白阵列检测信号通路,并在细胞系、患者来源异种移植模型及体内实验中验证。
主要发现
- 反向蛋白阵列显示LCK在泼尼松反应不良患者中异常激活。
- LCK抑制剂达沙替尼、博舒替尼、尼达尼布和WH-4-023可诱导糖皮质激素耐药T-ALL细胞死亡。
- 与地塞米松联用可逆转糖皮质激素耐药,即使在治疗药物浓度下。
- LCK基因沉默及泼尼松反应不良患者来源异种移植细胞的体外联合处理证实了上述结果。
- 泼尼松反应不良患者中LCK过度激活上调钙调磷酸酶/活化T细胞核因子信号,导致IL-4过表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric T-acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a high-risk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specific LCK gene silencing and ex vivo combined treatment of cells from PPR patient-derived xenografts. Moreover, we observed that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression. GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells. Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo. Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.
引用
- Serafin V, Capuzzo G, Milani G, et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood. 2017. PMID: 29101238. doi:10.1182/blood-2017-05-784603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。